Reverse transcription of retroviral RNA into linear doublestranded DNA and its integration into the host cell genome are essential steps in the retroviral life cycle. The nonhomologous end-joining (NHEJ) DNA repair pathway has been implicated in protecting cells from retrovirusinduced apoptosis caused by strand breaks in host cell DNA or unintegrated linear viral DNA. In eukaryotes, both the NHEJ and homologous recombination (HR) pathways play important roles in repairing DNA double-strand breaks. Here we show that the HR repair protein RAD52 modulates the outcome of recombinant HIV-l vector infection by markedly reducing the efficiency of productive integration events. Increased retroviral integration is the first major phenotype described for a RAD52 deficiency in mammalian cells. Mutations in other HR proteins (XRCC2, XRCC3 and BRCA2) do not markedly affect retroviral transduction rates, suggesting that the HR repair pathway per se does not influence retroviral infection. Instead, the mechanism of attenuation of retroviral infection by RAD52 appears to be based upon competition between the RAD52 protein and active integration complexes for the retroviral cDNA genome.
Introduction
The repair of DNA damage is an essential process by which cells maintain the integrity of their genome in order to prevent mutations, chromosomal aberrations and loss of genetic material. DNA double-strand breaks (DSBs) are particularly genotoxic forms of DNA damage because a single unrepaired DSB can lead to cell death via apoptosis (Huang et al, 1996; Rich et al, 2000) . The repair of DNA DSBs can occur through either homologous recombination (HR) or nonhomologous end joining (NHEJ) (Van Gent et al, 2001; Jackson, 2002) . Repair of DSBs by HR requires an undamaged homologous DNA sequence for use as a repair template to restore the integrity of the damaged DNA. Homology-directed DSB repair proceeds through either gene conversion or single-strand annealing (SSA) pathways (Paques and Haber, 1999; Johnson and Jasin, 2000) . Proteins involved in HR pathways are the so-called RAD52 group of proteins that includes RAD52, RAD51 and its paralogues XRCC2, XRCC3, RAD51B, RAD51C and RAD51D ). In addition, the BRCA1 and BRCA2 proteins, encoded by genes associated with breast cancer predisposition, have also been implicated in HR-directed gene conversion pathways (Moynahan et al, 1999 (Moynahan et al, , 2001 Davies et al, 2001) . Unlike HR, NHEJ does not require an undamaged DNA partner or extensive sequence homology but joins the broken ends of a DSB together. NHEJ repair requires the DNA-end-binding activity of the Ku70/80 heterodimer, its interacting partnerthe catalytic subunit of DNA-dependent protein kinase (DNAPKcs)-and the complex between DNA ligase IV and XRCC4 (Smith and Jackson, 1999) .
Reverse transcription and integration of viral doublestranded DNA into a host cell's genome are essential steps in the retroviral life cycle. These steps are mediated by the retroviral proteins reverse transcriptase (RT) and integrase (IN), respectively. After virus entry, the retroviral RNA is reverse transcribed by RT to produce a linear double-stranded DNA copy that includes directly repeated sequences at each end, known as long terminal repeats (LTRs). The linear retroviral cDNA is then 3 0 -recessed at both ends and joined to host cell chromosomal DNA via a direct trans-esterification reaction catalysed by IN. This strand transfer process results in short staggered DNA strand breaks in the host cell's DNA at the site of integration (Brown, 1997) . Host cell DNA repair proteins must effectively repair these gapped DNA intermediates in order to complete the integration process. Several host cell DNA repair proteins and pathways, including the NHEJ DNA repair pathway (Daniel et al, 1999; Li et al, 2001; Jeanson et al, 2002) , Poly(ADP-ribose)-polymerase (PARP; Gaken et al, 1996; Ha et al, 2001) , ataxia telangiectasia mutated (ATM; Daniel et al, 2001 ), ATM-Rad3-related (ATR; Daniel et al, 2003) and RAD18 proteins (Mulder et al, 2002) , have all been shown to be involved in the establishment of productive retroviral infections.
Loss of the NHEJ DNA repair pathway renders mammalian cells susceptible to apoptotic cell death following retroviral infection (Daniel et al, 1999; Li et al, 2001 ). Both host cell DNA damage caused by IN (Daniel et al, 1999) and excess retroviral double-stranded linear DNA resulting from RT activity (Li et al, 2001 ) may act as triggers for retrovirally induced apoptosis in NHEJ-deficient cells. Recent evidence also suggests that the NHEJ DNA repair pathway is responsible for the production of retroviral 2-LTR DNA circles that are generated from double-stranded linear cDNA (Li et al, 2001; Jeanson et al, 2002) . Consistent with the idea that NHEJ plays an important role in retroviral infections is the finding that Ku, a key protein in initiating NHEJ repair, is physically associated with the Ty1 retrotransposon (Downs and Jackson, 1999) and retroviral preintegration complexes (Li et al, 2001; Lin and Engelman, 2003) .
Although the involvement of the NHEJ DNA repair pathway in retroviral integration has been previously described, there is still little understanding of the role that might be played by HR-directed repair, the other major DNA DSB repair pathway. Here, we investigate both the role of the HR pathway in retroviral infection and the interplay between proteins associated with the HR and NHEJ pathways.
Results

Loss of RAD52 (but not other HR proteins) enhances retroviral infection
In mammalian cells, RAD51 is thought to be a critical component of the HR pathway and unlike the situation in yeast, disruption of RAD51 in mammalian cells results in cellular lethality (Lim and Hasty, 1996; Tsuzuki et al, 1996; Sonoda et al, 1998) . This unfortunately complicates any detailed analysis of the potential role of RAD51 in retroviral integration. However, mammalian cells also contain several paralogues and regulators of RAD51 function. Paralogues of RAD51 include the XRCC2 and XRCC3 proteins , while the breast cancer-associated protein BRCA2 has been implicated in mediating HR through RAD51 regulation (Davies et al, 2001; Moynahan et al, 2001) . Unlike RAD51 deficiency, mammalian cells are available that are impaired in XRCC2, XRCC3 and BRCA2 function and these cells are viable but show significantly reduced HR efficiency, chromosomal instability and associated sensitivity to DNA-damaging agents (Takata et al, 2001; Thompson and Schild, 2001) .
To determine what role, if any, the HR pathway plays in regulating mammalian retroviral integration, we used cells impaired in XRCC2, XRCC3 or BRCA2 and infected them with HIV-1 luciferase reporter gene vectors before determining transduction efficiencies using luciferase activity as a readout (see Supplementary information). Figure 1A and B demonstrate little if any effect on retroviral transduction efficiencies with the loss of these key components of the mammalian HR pathway. By contrast, cells deficient in RAD52 show a 16-fold increase in transduction rates ( Figure 1C ). The HIV luciferase transduction assay results of isogenic mouse embryonic stem (ES) cells with targeted deletions of none (Rad52
) Rad52 alleles also demonstrated that HIV-1 integration efficiency was sensitive to Rad52 gene dosage, since the deletion of one Rad52 allele also resulted in a 10-fold increase in transduction efficiency. Further evidence that RAD52 inhibits retroviral infection and that RAD52 deficiency leads to an increase in retroviral transduction was provided by RNA interference (RNAi) gene knockdown experiments using small interfering RNAs (siRNAs; Elbashir et al, 2001) . A RAD52 siRNA was used to knock down RAD52 expression in HeLa cells (see Supplementary information) before HIV-1 luciferase transduction assays were performed. Figure 1D shows that RAD52 siRNA-transfected cells demonstrate an increase in HIV-1 vector transduction efficiency when compared to cells transfected with a nonspecific control siRNA. These data are consistent with those seen for Rad52 knockout mouse ES Figure 1C) , although the relative increase in HIV-1 transduction efficiency is much lower at only two-to threefold over and above the control cells. This discrepancy could be due, in part, to the fact that siRNA knockdown is not 100% complete (see Supplementary information) with residual protein and activity remaining.
Overexpression of RAD52 inhibits HIV-1 infection and stable integration
Since the absence of RAD52 increases retroviral transduction, we wondered if its overexpression would have the converse effect. We generated a number of stably transfected HeLa cell lines containing either vector DNA or vector DNA expressing HA epitope-tagged RAD52. Overexpression of RAD52 was confirmed by immunoblot analysis of two independently isolated cell lines containing only vector DNA, and five cell lines containing the HA-RAD52-expressing vector. Both HA and RAD52 antibodies detected the overexpressed HA-RAD52 protein (Figure 2A ; antibodies against Ku70, Ku80 and b-actin served as controls). The level of endogenous RAD52 protein is very low and could not be detected efficiently with our antibody. HIV-1 luciferase transduction assays revealed that retroviral transduction is equally efficient in HeLa and vectoronly-transfected cell lines. However, in the HeLa cell lines overexpressing RAD52, transduction is reduced approximately five-fold ( Figure 2A ).
To determine if the effect of RAD52 was due to the impairment of stable integration or through some other process, we transduced both Rad52 Figure 2B ). In contrast, the RAD52-overexpressing HeLa clone (RAD52-3) shows a four-fold reduction in HIV-1 DNA compared to control cells (IRES-1). qPCR was also performed using primers that detect unintegrated 2-LTR HIV-1 DNA (Butler et al, 2001) . 2-LTR sequences were undetectable (see Supplementary information), indicating that the late HIV-1 RT DNA amplified in Figure 2B corresponds to integrated proviral DNA. Quantitative HIV-Alu PCR (Butler et al, 2001) was not used to determine proviral DNA content since mouse DNA does not contain Alu sequences. These qPCR results are in line with those seen for the HIV luciferase transduction assays (Figures 1C and 2A) and indicate that RAD52 acts primarily through impairing stable HIV-1 integration events.
The DNA-binding activity of RAD52 is required to inhibit HIV-1 transduction
The function of RAD52 in HR requires its interaction with both RPA and RAD51 (Paques and Haber, 1999) . If the observed effect of RAD52 on retroviral transduction is indeed independent of its role in HR, then the domain of RAD52 required for interaction with RPA and RAD51 should be dispensable for the repression of transduction. Two different internal deletion mutants of RAD52 were tested for their ability to modulate retroviral transduction.
The first lacks amino-acid residues 43-177, which span the RAD52 multimerisation and DNA-binding domains ( Figure 3A ; Shen et al, 1996a, b) . The second mutant lacks residues 195-347, which encompass the RPA and RAD51 interaction domains (Park et al, 1996) . Plasmids expressing full-length RAD52 or either of the two deletion mutants were transiently transfected in 293 cells and the expression of the RAD52 derivative was confirmed by immunoblotting ( Figure 3B ). HIV-1 luciferase transduction assays demonstrated that only the DNA-binding and self-interaction domains of RAD52, and not the RPA and RAD51 interaction domains, were required for the repression of retroviral transduction ( Figure 3B ). Since the loss of the RPA interaction domain has previously been shown to abolish the ability of RAD52 to stimulate HR (Park et al, 1996) , this is consistent with data in Figure 1A and B, which suggest that HR repair activities do not directly influence the course of retroviral infections. However, the requirement for the DNA-binding activity of RAD52 suggests that a physical DNA interaction, possibly with HIV-1 DNA, is necessary to elicit the observed inhibitory effects of RAD52 on retroviral transduction.
To test whether RAD52 can bind to HIV-1 DNA, chromatin immunoprecipitation (ChIP) assays were performed on 293 cells transiently transfected with RAD52 expression plasmids and transduced with the HIV-1 luciferase vector ( Figure 3C ). Immunoprecipitations using whole-cell extracts were carried out with antibodies against HA-RAD52 and with nonspecific controls (no antibody and isotype IgG1 anti-FLAG antibody). Associated DNA was then detected in a semiquantitative manner using PCR for HIV-1 LTR or genomic GAPDH gene sequences. Figure 3C demonstrates that full-length RAD52 is indeed associated with HIV-1 DNA, since HIV-1 LTR DNA sequences were readily amplified from HA ChIPs but not from nonspecific control ChIPs. As predicted, the RAD52 D43-177 DNA-binding mutant shows a greatly reduced affinity for HIV-1 DNA, whereas this is not the case for the D195-347 mutant. GAPDH DNA was not readily amplified in any ChIP, demonstrating the specificity of association of RAD52 with HIV-1 LTR DNA.
RAD52 competes with Ku for binding to HIV-1 LTR DNA
Since we had observed a gene dosage effect of RAD52 on retroviral transduction efficiency in the mouse ES cells ( Figure 1C ), we investigated whether the level of RAD52 protein could also influence the repression of transduction in human cells. 293 cells were transiently transfected with increasing amounts of RAD52 expression plasmid DNA, and immunoblot analysis of the cells demonstrated that RAD52 protein levels correlated with the amount of transfected plasmid ( Figure 4A ). In HIV luciferase transduction assays, we were able to demonstrate that the efficiency of retroviral transduction does indeed decrease in correlation with increasing amounts of RAD52 protein ( Figure 4A ). The gene dosage effect of RAD52 on retroviral transduction ( Figures 1C  and 4A) , coupled with the observation that only RAD52 DNA binding is required to elicit this effect (Figure 3) , suggests a possible mechanism of inhibition involving competition for the binding of HIV-1 cDNA intermediates between RAD52 and proteins involved in HIV-1 integration.
One such competing protein might be Ku. A number of studies have shown that Ku and NHEJ DNA repair are required for efficient retroviral transduction (Daniel et al, 1999; Li et al, 2001; Jeanson et al, 2002) and that Ku is physically associated with retroviral preintegration complexes (Li et al, 2001; Lin and Engelman, 2003) , presumably bound to cDNA ends. The ability of RAD52 to inhibit retroviral transduction could, therefore, be due to competition with Ku for viral cDNA.
To test this possibility, competitive PCR-ChIP assays were performed on 293 cells transfected with increasing amounts of RAD52 expression plasmid DNA and transduced with the HIV-1 luciferase vector. For all transfections, the total amount of DNA was kept constant (24 mg) by adding vector-only plasmid DNA. ChIPs were performed using antibodies against Ku80 and HA-tagged RAD52, and the amount of HIV-1 LTR DNA immunoprecipitated by each antibody was assessed by PCR ( Figure 4B ). This analysis demonstrates that in cells with high levels of RAD52 protein expression there is a much greater amount of RAD52 associated with HIV-1 LTR DNA (anti-HA ChIPs) compared with those with low levels of RAD52 protein expression. Importantly, anti-Ku80 ChIPs reveal the opposite finding, with cells expressing high levels of RAD52 demonstrating significantly reduced levels of Ku80-associated HIV-1 LTR DNA compared to cells with low RAD52 levels. The immunoblots of input extracts using HA and Ku80 antibodies, shown in Figure 4C , confirm that RAD52 protein expression levels correlate with the amount of expression plasmid transfected and that Ku80 expression remains unaffected. Together, these data support the hypothesis that RAD52 competes with Ku for binding to HIV-1 LTRs.
RAD52 suppresses 2-LTR circle DNA formation but does not enhance apoptosis
Previously, it has been established that proteins involved in NHEJ, including Ku, are required for the formation of retroviral 2-LTR circle DNA (Li et al, 2001; Jeanson et al, 2002) . Since the absence of RAD52 and Ku has opposing effects on retroviral transduction efficiency, we assessed the efficiency of 2-LTR circle DNA formation (a possible indicator of NHEJ activity) in cells expressing different amounts of RAD52. The relative amounts of 2-LTR circle DNA were estimated by semiquantitative PCR analyses of DNA extracted from both Rad52 þ / þ or Rad52 À/À ES cells infected with HIV-1 ( Figure 5A ) and on HIV-1-infected 293 cells transfected with expression plasmids for full-length RAD52 or RAD52 Figure 5A) shows that 2-LTR circle DNA appeared at a similar rate in both Rad52 þ / þ and Rad52 À/À cells at early times postinfection (4 h) but then accumulated to higher levels in Rad52 À/À cells at later time points (particularly noticeable after 18 h). The 2-LTR circle DNA was also maintained at peak levels for longer (18-24 h) in Rad52
D43-177 DNA-binding-deficient mutant (Figure 5B). Analysis of mouse ES cells (
À/À cells. By contrast, in 293 cells overexpressing full-length RAD52 ( Figure 5B ), 2-LTR circle DNA formation was significantly impaired, but not so in cells overexpressing the RAD52 D43-177 mutant that is incapable of repressing retroviral transduction (Figure 3 ). These data therefore indicate that the loss or gain of RAD52 can lead to the modulation of HIV-1 2-LTR circle DNA formation. In addition to affecting HIV-1 2-LTR circle formation, Ku and the NHEJ apparatus have been implicated in protecting cells from retrovirus-induced apoptosis (Daniel et al, 1999; Li et al, 2001 ). In the study by Li et al (2001) it was suggested that 2-LTR circle DNA formation mediated by NHEJ could be directly responsible for protection from apoptosis, since it may remove potentially proapoptotic retroviral cDNA ends formed after reverse transcription. If this model is correct, then we might expect a correlation between RAD52 inhibition of 2-LTR circle DNA formation and increased apoptosis of HIV-1-infected cells. HIV-1 vector-induced apoptosis was assessed for both HeLa cells and RAD52-overexpressing HeLa clones RAD52-3 and -5. The proportion of cells undergoing apoptosis was determined by annexin-V staining and the proportion of live/dead cells was determined by propidium iodide (PI) counter-staining. Our results show that the extent of apoptosis between HeLa and the RAD52-overexpressing clones was not significantly different ( Figure 5C and D). Both early-stage apoptosis (high annexin-V but low PI staining) and the total apoptotic/dead (all annexin-V-positive cells) populations were not increased in either of the two RAD52-overexpressing HeLa clones. To confirm these results, apoptosis/cell death was also assessed using caspase-activation assays and trypan blue staining. Equivalent results were obtained (data not shown) indicating no demonstrable differences between the cell lines. Similar apoptosis analyses using 293 cells transiently transfected with the RAD52 expression plasmid or with Rad52 À/À mouse ES cells also failed to
show any major differences in HIV-1 vector-induced apoptosis when compared to control cells (data not shown). These results therefore indicate that despite the effect on retroviral transduction efficiency and NHEJ-mediated 2-LTR circle DNA formation, RAD52 does not appear to influence HIV-1-induced apoptosis.
Discussion
The data presented have shown that the HR protein RAD52 suppresses retroviral infection in mammalian cells. Retroviral transduction can be increased by as much as 16-fold in the absence of RAD52. Previously, no overt phenotype resulting from the lack of RAD52 had been detected in mammalian cells and the results presented here represent the most dramatic in vivo effect of RAD52 inactivation to date. The absence of Rad52 in mice, for example, does not result in DNA damage sensitisation, cancer predisposition or defects associated with meiotic recombination (Rijkers et al, 1998) .
In fact, the only HR defect detected in Rad52 À/À mouse ES cells was a modest (1.5-fold) reduction in homologous gene targeting. Although no overt DNA repair phenotypes are associated with RAD52 deficiency in mammalian cells, genetic and biochemical experiments have revealed that RAD52 plays a major role in HR (Kanaar and Hoeijmakers, 1998) . Our results indicate, however, that the HR function of RAD52 is not involved in attenuating retroviral infection because other proteins required for HR, such as XRCC2, XRCC3 and BRCA2, do not greatly influence the outcome of HIV-1 infections, either positively or negatively (Figure 1) . Thus, the HR DSB repair pathway is superfluous with respect to establishing productive retroviral integration. Two other observations further support this notion. Firstly, the domain of RAD52 responsible for interaction with other HR proteins is not required for the suppression of retroviral infection. Instead, this activity resides in the DNA-binding and RAD52 selfinteraction domain (Figure 3) . Secondly, suppression can be achieved by the overexpression of RAD52 alone and occurs in a dose-dependent manner (Figure 4) . Analysis of 2-LTR circle DNA during retroviral infection, a process that requires Ku and NHEJ repair (Li et al, 2001; Jeanson et al, 2002) , shows that its formation can be modulated by the levels of RAD52 expression ( Figure 5 ). These observations, coupled with the demonstration that RAD52 can compete with and effectively displace Ku from the ends of HIV-1 cDNA ( Figure 4B ), indicate that RAD52 can interfere with Ku-directed NHEJ repair activity. The exact mechanism of this competition, however, is far from clear. Although it has been proposed that RAD52 may directly compete with Ku for DNA ends (Van Dyck et al, 1999) , it is also possible that single-stranded DNA character at the ends of the retroviral LTRs could mean that RAD52 has an indirect effect on Ku binding. Without knowing the exact nature of retroviral LTR DNA in infected cells and the way in which RAD52 and Ku proteins bind to the LTRs, it is difficult to distinguish between these possibilities.
Previous studies have shown that Ku deficiency is associated with both the loss of 2-LTR circle DNA formation (Li et al, 2001; Jeanson et al, 2002) and increased apoptosis (Daniel et al, 1999; Li et al, 2001 ) following retroviral infection. It has been speculated that the formation of 2-LTR circle DNA and the induction of apoptosis are directly linked. One NHEJ-dependent cell survival model (Li et al, 2001 ) argues for a direct physical elimination mechanism whereby linear retroviral cDNA ends that represent proapoptotic signals are removed through circularisation by the Ku-dependent NHEJ pathway, thereby protecting the host cell from apoptosis. In a simple extension of this model, the prevention of Ku binding to the retroviral LTRs, either through the absence of Ku or alternatively when RAD52 competes with Ku for retroviral LTR DNA, should result in an abrogation of NHEJ activity, a decrease in the number of 2-LTR DNA circles observed and apoptosis of the host cell resulting in a nonproductive infection. This simple RAD52-Ku competition model for retroviral suppression, while attractive, is not consistent with our experimental observations. Significantly, we have been unable to demonstrate any substantial differences in the level of HIV-1-induced cell killing in either Rad52 À/À or in RAD52-overexpressing cells (Figure 5 ), as might be predicted. This means that although RAD52 affects the end-joining activity of Ku, it does not interfere with Ku-dependent protection from retrovirus cDNA-induced apoptosis. This disparity can only be explained if either the removal of the proapoptotic linear retroviral cDNA through LTR circle formation is not required for apoptosis suppression or linear retroviral DNA can be removed by alternative pathways. The possibility that LTR circle DNA formation and apoptosis suppression are not directly linked has been suggested as an alternative model in which to explain earlier (Li et al, 2001 ) and more recent (Kilzer et al, 2003) observations. Certainly, the data presented here suggest that the role of Ku and the NHEJ pathway in preventing HIV-1-induced apoptosis is, in fact, more complex than was initially envisaged. The findings presented here therefore require the invocation of an alternative hypothesis in order to explain the RAD52 suppression of retroviral integration, because the inhibitory activity of RAD52 on HIV-1 infection cannot be explained through the modulation of cell survival. Our data suggest that HIV-1 transduction is influenced as a direct consequence of the binding of RAD52 to HIV-1 cDNA and that this binding correlates with a decrease in the number of stable integration events. The simplest explanation therefore is that RAD52 can suppress HIV-1 integration. Although beyond the scope of this study, it could be envisaged that RAD52 may prevent the association of other retroviral cDNAbinding proteins, in addition to Ku, that form part of the preintegration complex (Bowerman et al, 1989) . Candidate proteins that might be affected include integration cofactors such as Ini1 (Kalpana et al, 1994) , HMG I(Y) (Farnet and Bushman, 1997) , BAF (Lee and Craigie, 1998) as well as the viral IN or RT proteins themselves. In addition, the postreplication/translesion DNA repair protein RAD18 has been shown to interact with HIV-1 IN (Mulder et al, 2002) and studies in yeast have shown that DNA repair pathway switching involving the Srs2 helicase can be modulated by both RAD18 and RAD52 (Broomfield et al, 2001) . These observations therefore provide a possible link between RAD52, RAD18 and HIV-1 integration.
Based on our data, we propose a model in which suppression of retroviral infection by RAD52 may be due to the effective capping of retroviral cDNA ends by RAD52 such that the loading or recruitment of other proteins or complexes required for efficient reverse transcription or integration is blocked. In this model, the major influence of RAD52 is through inhibition of integration and not through the enhancement of apoptosis. This model is only likely to be valid, however, if there are differences between the binding characteristics of Ku and RAD52, such that Ku can bind to the viral cDNA while still accommodating (or perhaps enhancing) the binding of RT or IN and its associated cellular cofactors, while RAD52 inhibits cofactor binding. In this regard, it is notable that multiple Ku subunits can load onto and translocate along the DNA strand (Yoo and Dynan, 1999) , which would be potentially compatible with the recruitment of additional proteins, such as IN, to the ends of the viral cDNA. Also consistent with this idea are data demonstrating that Ku does not affect the cleavage or strand-transfer activities of the IN protein in vitro (Li et al, 2001) . The competitive involvement of Ku and RAD52 proteins in retrovirus transduction suggests that DNA repair pathways may represent another cellular process that is hijacked by viruses to complete their infectious cycles. Modulation of NHEJ or HR DNA repair proteins therefore provides the potential to regulate viral infection. For example, by targeting the NHEJ pathway and its associated signalling pathways, it may be possible to repress retroviral infections. Alternatively, inhibition of RAD52 gene expression could lead to a considerable enhancement of retroviral vector-based gene transduction, significantly increasing the potential of retroviral-based gene therapy.
Materials and methods
Expression vectors
RAD52 cDNA was cloned in-frame with an HA epitope in pIRESneo2 (Clontech) to yield the expression plasmid pIREsneo2-HA-RAD52. RAD52 deletion mutants D43-177 and D195-347 were made by digestion of RAD52 cDNA with Bsu36I-HinDIII and BglII-XbaI respectively, then blunt-ending with Klenow DNA polymerase before re-ligation. These deletions maintained the reading frame of RAD52. Antibodies RAD52 antibody (H-300) was obtained from Santa Cruz Biotechnology; HA antibodies from Boehringer Mannheim (12CA5) and Sigma (HA7); the Ku70 (S5C11) and Ku80 (111) antibodies from NeoMarkers-Labvision Corp.; and the FLAG (M2) and b-actin (AC-15) antibodies from Sigma.
Cell lines
HeLa and 293 cells were grown in DMEM with 10% FBS (Invitrogen). Mouse ES cell line 1B10 (Rad52 þ / þ ) and its Rad52 þ /À and Rad52 À/À derivatives (Rijkers et al, 1998) were grown on gelatinised dishes in DMEM with 15% FBS and 1000 U/ml leukaemia inhibitory factor (ESGRO, Chemicon International Inc.). V79 (XRCC2 þ ) and the XRCC2-defective derivative IRS1 (Jones et al, 1995; Thacker et al, 1995) , AA8 (XRCC3 þ ) and its XRCC3-defective derivative IRS1-SF (Tebbs et al, 1995) hamster cell lines and the BRCA2-defective cell line Capan-1 (Abbott et al, 1998) and BxPC3 (BRCA2 þ ) human pancreatic cell lines have been described previously. HeLa-IRES and HeLa-RAD52 stable clones were made by transfection of HeLa cells with pIRESneo2HA and pIRESneo2-HA-RAD52 plasmids, respectively. Individual clones were expanded after selection with 500 mg/ml G418 (Invitrogen). RAD52-overexpressing clones were identified by immunoblot analysis with HA and RAD52 antibodies.
Recombinant HIV-1 vectors and retrovirus production
Recombinant HIV-1 retroviral stocks were produced by transient cotransfection of the HIV-1 gag/pol-packaging constructs LDP2GPH (Haselhorst et al, 1998) , HIV-1 luciferase transfer vector pHR'Luc and VSVG envelope expression plasmids (Naldini et al, 1996) . HIV-1 viral titres were estimated using the HIV-1 p24 gag antigen ELISA kit (Beckman-Coulter).
Retroviral infection and luciferase assays
For HIV-1 luciferase transduction assays, cells were seeded in white 96-well plates and exposed to retroviral stocks at an MOI of 0.5. Luciferase activity, which will only occur after successful transduction (see Supplementary information), was quantified 48-72 h postaddition of virus on a Packard TopCount-NXT microplate scintillation counter using Bright-Glo luciferase assay reagent (Promega Corporation). For coupled, transient RAD52 transfection-retrovirus transduction assays, 293 cells were transfected with expression plasmid DNA using Lipofectamine-2000 reagent (Invitrogen). At 24 h post-transfection, cells were exposed to retroviral stocks at an MOI of 0.5. At 48 h postaddition of virus, cells were harvested in passive lysis buffer (PLB; Promega Corporation) and samples split for analysis of protein expression by immunoblot and HIV-1 infectivity by luciferase activity.
RAD52 siRNA knockdown experiments RAD52 siRNA (target sequence: AAAGACUACCUGAGAUCACUA) and nonspecific control siRNA (AAATTCTATCACTAGCGTGAC) were synthesised and preduplexed by Dharmacon Inc. HeLa cells were transfected with 100 nM siRNA duplexes (see Supplementary information) before performing HIV-1 luciferase assays.
PCR analysis of HIV-1 cDNA forms
Infected cells were harvested in PBS with 100 mg/ml RNase A (Sigma) at room temperature for 10 min. Samples were heated at 951C for 10 min and then digested with 300 mg/ml proteinase K at 561C for 4 h. DNA was isolated by ethanol precipitation in the presence of yeast tRNA carrier. PCR analysis of HIV-1 cDNA forms using primers for 2-LTR circle DNA (primers LTR8 and LTR9) was performed as described by Naldini et al (1996) . GAPDH PCR was performed with primer pairs GA3 (AGGTCCACCACCCTGTTGC) and GA5 (AGAAGACTGTGGATGGCCCC). All PCR reactions were limited to 20-26 cycles to ensure linearity of amplification. Bands were detected by Southern blot and hybridisation to 32 P-labelled HIV-LTR or GAPDH cDNA probes (Rediprime kit, Amersham-Pharmacia). Bands were quantified by densitometry using the Cyclone phosphoimaging system (Packard). For some experiments, quantitative real-time PCR analysis of late HIV-1 DNA was performed as described by Butler et al (2001) using an ABI Prism 7000 Sequence Detection System. Here, late RT HIV-1 DNA was quantified from 50 ng of total genomic DNA in 25 ml reactions. PCR standards were obtained from serially diluted genomic DNA isolated from HeLa cells 24 h after transduction with retroviral stocks and made up to 50 ng in uninfected genomic DNA. Control qPCRs for unintegrated 2-LTR HIV-1 DNA and GAPDH (total genomic) DNA were also performed for each sample (see Supplementary information).
HIV-1 chromatin immunoprecipitations
293 cells were seeded in multiple 10-cm dishes and transfected with plasmid DNA using Lipofectamine-2000 reagent (Invitrogen). At 24 h post-transfection, cells were exposed to retroviral stocks at an MOI of 0.25. DNA-protein interactions were then fixed with formaldehyde (final concentration 1%) at 371C for 10 min. Cells were sonicated four times in 10 s pulses in sonication buffer (50 mM Tris pH 8.0, 1% SDS, 10 mM EDTA, protease inhibitors). Immunoprecipitation of protein-DNA complexes was performed using 2-4 mg of cell supernatants per antibody that were diluted in IP buffer (20 nM Tris pH 8.0, 0.1% SDS, 2 mM EDTA, 1% Triton X-100, 50 mM NaCl, protease inhibitors) and precleared for 1 h with protein-G-Sepharose beads (Amersham-Pharmacia). Small aliquots for protein and DNA input samples were taken at this point. Antibodies were added (2-4 mg per mg of precleared cell supernatant) with 41C overnight incubation. Protein-G-Sepharose beads were added and incubated for 2 h. Beads were washed twice in lowsalt buffer (IP buffer þ 150 mM NaCl), twice in high-salt buffer (IP buffer þ 500 mM NaCl), once in LiCl wash buffer (10 mM Tris pH 8.0, 1 mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate, 250 mM LiCl) and twice in TE. Protein-DNA complexes were extracted in elution buffer (50 mM Tris pH 8.0, 1% SDS, 100 mM NaHCO 3 , 10 mM EDTA) and crosslinks reversed by adding 200 mM NaCl and heating at 651C for 4 h. DNA was purified after proteinase K digestion, phenol:chloroform:IAA extraction and ethanol precipitation. HIV-1 DNA was detected by PCR using primers LTR5 and LTR6 (Naldini et al, 1996) as described.
Cell viability and apoptosis assays Cells were exposed to retroviral stocks at an MOI of 10. Cells were harvested and apoptotic/dead cells were stained by incubation with annexin-V and PI (BD Pharmingen). The numbers of live (annexin-V/PI negative), early apoptotic (annexin-V positive/PI negative) and late apoptotic/dead (annexin-V/PI positive) cells were quantified by flow cytometric analysis using a BD FACScalibur and CellQuest software.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
